{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-26-000696","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2026-05-27T11:00:48+00:00","discovered_at":"2026-05-27T11:05:00.258466+00:00","generated_at":"2026-05-27T11:07:31.023411+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunic appoints Erik Lundgren as CEO; Daniel Vitt resigns as CEO but remains on board","bullets":["Erik Lundgren appointed CEO effective June 1, 2026; previously SVP at Genentech/Roche, led Ocrevus launch.","Daniel Vitt resigns as CEO but retains board seat and responsibility for scientific strategy.","Lundgren receives base salary $685K, target bonus 60%, and initial option for 1M shares under inducement plan.","Phase 3 ENSURE trial in relapsing MS expected data readout by year-end 2026; Lundgren to lead toward potential NDA and commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-000696","json":"https://secwatch.observer/filing/0001193805-26-000696.json","markdown":"https://secwatch.observer/filing/0001193805-26-000696.md","text":"https://secwatch.observer/filing/0001193805-26-000696.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000696/0001193805-26-000696-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000696/e665513_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T11:07:31.023411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"974f1a6bfc","claim":"Erik Lundgren was appointed as Chief Executive Officer at IMMUNIC, INC..","evidence_excerpt":"On May 22, 2026 (the “Effective Date”), Immunic, Inc. (the \"Company\") appointed Erik Lundgren, as Chief Executive Officer of the Company, with his start of employment beginning on June 1, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000696/0001193805-26-000696-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001193125-26-251709","ticker":"CRVL","company_name":"CORVEL CORP","filed_at":"2026-06-01T21:05:42+00:00","headline":"CorVel CEO Michael Combs to become Executive Chair; Sarah Scott appointed CEO and President effective July 1, 2026","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 7.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251709","json":"https://secwatch.observer/filing/0001193125-26-251709.json","markdown":"https://secwatch.observer/filing/0001193125-26-251709.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/0001193125-26-251709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/d24231d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 22, 2026 (the “Effective Date”), Immunic, Inc. (the \"Company\") appointed Erik Lundgren, as Chief Executive Officer of the Company, with his start of employment beginning on June 1, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000696/0001193805-26-000696-index.htm","comparable_excerpt":"In connection with the leadership transition, the Board appointed Sarah Scott to serve as Chief Executive Officer and President of the Company, effective July 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/0001193125-26-251709-index.htm"}},{"accession":"0000105770-26-000080","ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-06-01T20:32:30+00:00","headline":"West Pharmaceutical appoints Michel Lagarde as CEO; Green retires, Friel becomes Chair","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 7.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-26-000080","json":"https://secwatch.observer/filing/0000105770-26-000080.json","markdown":"https://secwatch.observer/filing/0000105770-26-000080.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/wst-20260531.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 22, 2026 (the “Effective Date”), Immunic, Inc. (the \"Company\") appointed Erik Lundgren, as Chief Executive Officer of the Company, with his start of employment beginning on June 1, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000696/0001193805-26-000696-index.htm","comparable_excerpt":"As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm"}},{"accession":"0001193125-26-251522","ticker":"VRRM","company_name":"VERRA MOBILITY Corp","filed_at":"2026-06-01T20:29:13+00:00","headline":"Verra Mobility CEO David Roberts steps down amid cost realignment; interim CEO Keyser appointed","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 7.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251522","json":"https://secwatch.observer/filing/0001193125-26-251522.json","markdown":"https://secwatch.observer/filing/0001193125-26-251522.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682745/000119312526251522/0001193125-26-251522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682745/000119312526251522/d39754d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 22, 2026 (the “Effective Date”), Immunic, Inc. (the \"Company\") appointed Erik Lundgren, as Chief Executive Officer of the Company, with his start of employment beginning on June 1, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000696/0001193805-26-000696-index.htm","comparable_excerpt":"On June 1, 2026, Verra Mobility Corporation (the “Company”) announced that the Board of Directors of the Company (the “Board”) approved the appointment of Jonathan Keyser as the Interim President and Chief Executive Officer of the Company, effective May 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1682745/000119312526251522/0001193125-26-251522-index.htm"}},{"accession":"0001193125-26-251467","ticker":"PENG","company_name":"Penguin Solutions, Inc.","filed_at":"2026-06-01T20:17:28+00:00","headline":"Penguin Solutions CFO Nate Olmstead to step down; Aaron Johnson named interim CFO; reaffirms FY2026 guidance at high end","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 7.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251467","json":"https://secwatch.observer/filing/0001193125-26-251467.json","markdown":"https://secwatch.observer/filing/0001193125-26-251467.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1616533/000119312526251467/0001193125-26-251467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1616533/000119312526251467/d104493d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 22, 2026 (the “Effective Date”), Immunic, Inc. (the \"Company\") appointed Erik Lundgren, as Chief Executive Officer of the Company, with his start of employment beginning on June 1, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000696/0001193805-26-000696-index.htm","comparable_excerpt":"On May 31, 2026, the board of directors of the Company appointed Aaron Johnson, the Company’s Vice President, Finance and Accounting, as interim CFO and as the Company’s principal financial and accounting officer, succeeding Mr. Olmstead in these positions effective as of July 9, 2026, on an interim basis until the Company appoints a successor.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1616533/000119312526251467/0001193125-26-251467-index.htm"}},{"accession":"0001193125-26-250020","ticker":"NSC","company_name":"NORFOLK SOUTHERN CORP","filed_at":"2026-06-01T13:15:16+00:00","headline":"Norfolk Southern COO John Orr resigns; Brian Barr appointed successor effective June 1","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 7.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-250020","json":"https://secwatch.observer/filing/0001193125-26-250020.json","markdown":"https://secwatch.observer/filing/0001193125-26-250020.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/702165/000119312526250020/0001193125-26-250020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/702165/000119312526250020/d91653d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 22, 2026 (the “Effective Date”), Immunic, Inc. (the \"Company\") appointed Erik Lundgren, as Chief Executive Officer of the Company, with his start of employment beginning on June 1, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000696/0001193805-26-000696-index.htm","comparable_excerpt":"On May 31, 2026, John Orr, Executive Vice President & Chief Operating Officer of Norfolk Southern Corporation (the “Company”), notified the Company of his intention to resign from the Company for “good reason” on account of proposed changes in the Company’s operations that would result in a diminution of his duties and responsibilities.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/702165/000119312526250020/0001193125-26-250020-index.htm"}},{"accession":"0001213900-26-063165","ticker":"ADTX","company_name":"Aditxt, Inc.","filed_at":"2026-06-01T12:30:22+00:00","headline":"Aditxt names Jeffrey M. Busch Interim CEO; Amro Albanna steps down","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 7.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063165","json":"https://secwatch.observer/filing/0001213900-26-063165.json","markdown":"https://secwatch.observer/filing/0001213900-26-063165.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026063165/0001213900-26-063165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026063165/ea0292902-8k_aditxt.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 22, 2026 (the “Effective Date”), Immunic, Inc. (the \"Company\") appointed Erik Lundgren, as Chief Executive Officer of the Company, with his start of employment beginning on June 1, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000696/0001193805-26-000696-index.htm","comparable_excerpt":"On May 29, 2026, Amro Albanna notified the Company of his decision to resign as Chief Executive Officer of Aditxt, Inc. (the “Company”), and on May 30, 2026, Mr. Albanna resigned as a member of the Company’s Board of Directors (the “Board”), effective immediately.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026063165/0001213900-26-063165-index.htm"}},{"accession":"0001193125-26-249850","ticker":"RPD","company_name":"Rapid7, Inc.","filed_at":"2026-06-01T12:29:24+00:00","headline":"Rapid7 appoints Wael Mohamed CEO; Corey Thomas becomes Executive Chairman; reaffirms 2026 guidance","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 7.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-249850","json":"https://secwatch.observer/filing/0001193125-26-249850.json","markdown":"https://secwatch.observer/filing/0001193125-26-249850.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1560327/000119312526249850/0001193125-26-249850-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1560327/000119312526249850/d109829d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 22, 2026 (the “Effective Date”), Immunic, Inc. (the \"Company\") appointed Erik Lundgren, as Chief Executive Officer of the Company, with his start of employment beginning on June 1, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000696/0001193805-26-000696-index.htm","comparable_excerpt":"the Board appointed Marc Brown, who previously served as Chairman of the Board, as Lead Independent Director, effective June 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1560327/000119312526249850/0001193125-26-249850-index.htm"}},{"accession":"0001193125-26-249799","ticker":"SNDA","company_name":"SONIDA SENIOR LIVING, INC.","filed_at":"2026-06-01T12:09:00+00:00","headline":"Sonida Senior Living appoints Anton Nikodemus as COO effective June 15, 2026; base salary $550,000","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 7.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-249799","json":"https://secwatch.observer/filing/0001193125-26-249799.json","markdown":"https://secwatch.observer/filing/0001193125-26-249799.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1043000/000119312526249799/0001193125-26-249799-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1043000/000119312526249799/d11551d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On May 22, 2026 (the “Effective Date”), Immunic, Inc. (the \"Company\") appointed Erik Lundgren, as Chief Executive Officer of the Company, with his start of employment beginning on June 1, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000696/0001193805-26-000696-index.htm","comparable_excerpt":"On June 1, 2026, the Board of Directors (the “Board”) of Sonida Senior Living, Inc. (the “Company”) appointed Anton Nikodemus as Executive Vice President and Chief Operating Officer of the Company, effective June 15, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1043000/000119312526249799/0001193125-26-249799-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}